Abstract
There is growing evidence from in vitro studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46, correlates with the grade of malignancy of cervical cancer in situ. We also demonstrate the in vivo properties of Ad5-based vectors that contain the B-group Ad serotype 35 fiber (Ad5/35) in transgenic mice that express CD46 in a pattern and at a level similar to humans. Upon intravenous and intraperitoneal injection, an Ad5/35 vector did not efficiently transduce normal tissue, but was able to target metastatic or intraperitoneal tumors that express CD46 at levels comparable to human tumors. When an oncolytic Ad5/35-based vector was employed, in both tumor models antitumor effects were observed. Furthermore, injection of Ad5/35 vectors into CD46 transgenic mice caused less innate toxicity than Ad5 vectors. Our data demonstrate that Ad vectors that target CD46 offer advantages over Ad5-based vectors for treatment of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shenk T . Adenoviridea. In: Fields BN, Knipe DM, Howley PM (eds) Fields Virology. vol.2 Lippincott-Raven Publisher: Philadelphia, 1996 pp 2111–2148.
Law LK, Davidson BL . What does it take to bind CAR? Mol Ther 2005; 12: 599–609.
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309–319.
Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT . The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031–5036.
Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–330.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.
Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738–5748.
Gaggar A, Shayakhmetov D, Lieber A . CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408–1412.
Segerman A, Arnberg N, Erikson A, Lindman K, Wadell G . There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J Virol 2003; 77: 1157–1162.
Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N . Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77: 9183–9191.
Kinugasa N, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Ishizaki M et al. Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer 1999; 80: 1820–1825.
Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB et al. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000; 76: 176–182.
Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M . Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109–123.
Muruve DA . The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157–1166.
Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu X et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 2002; 6: 342–348.
Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, Lieber A et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004; 6: 631–641.
Sova P, Ren X-W, Shaoheng N, Bernt KM, Mi J, Kiviat N et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496–509.
Shayakhmetov DM, Li ZY, Ni S, Lieber A . Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004; 78: 5368–5381.
Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A . Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005; 16: 664–677.
Hsu EC, Dorig RE, Sarangi F, Marcil A, Iorio C, Richardson CD . Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding. J Virol 1997; 71: 6144–6154.
Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172: 6290–6297.
Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004; 22: 3035–3044.
Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18: 1213–1216.
Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T . Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003; 8: 813–821.
Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311: 384–393.
Shayakhmetov DM, Li ZY, Ni S, Lieber A . Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62: 1063–1068.
Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B . Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 2002; 3: 659–666.
Buchholz CJ, Schneider U, Devaux P, Gerlier D, Cattaneo R . Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. J Virol 1996; 70: 3716–3723.
Hsu KH, Lonberg-Holm K, Alstein B, Crowell RL . A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 1988; 62: 1647–1652.
Bernt K, Liang M, Ye X, Ni S, Li ZY, Ye SL et al. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J Virol 2002; 76: 10994–11002.
Carlson CA, Shayakhmetov DM, Lieber A . An adenoviral expression system for AAV Rep78 using homologous recombination. Mol Ther 2002; 6: 91–98.
Grunau C, Clark SJ, Rosenthal A . Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001; 29: E65.
Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar A, Gharwan H, Lieber A . The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 2003; 77: 3712–3723.
Vrancken Peeters MJ, Perkins AL, Kay MA . Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 1996; 20: 278–285.
Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.
Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8: 121–127.
Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM . Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 2003; 100: 1943–1948.
Shayakhmetov DM, Li Z-Y, Ni S, Lieber A . Analysis of adenovirus liver sequestration, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004; 78: 5368–5381.
Shayakhmetov S, Li Z-Y, Ni S, Lieber A . Interference with the IL-1 signaling pathway significantly improves the toxicity profile of systemically applied adenovirus vectors. J Immunol 2005; 174: 7310–7319.
Anderson BD, Nakamura T, Russell SJ, Peng KW . High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919–4926.
Frampton JE, Plosker GL . Icodextrin: a review of its use in peritoneal dialysis. Drugs 2003; 63: 2079–2105.
Engler H, Machemer TR, Schluep T, Wen SF, Quijano E, Wills KN et al. Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice. Mol Ther 2003; 7: 558–564.
Hakulinen J, Junnikkala S, Sorsa T, Meri S . Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 2004; 34: 2620–2629.
Seya T, Hara T, Iwata K, Kuriyama S, Hasegawa T, Nagase Y et al. Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients’ sera. Int Immunol 1995; 7: 727–736.
Stone D, Ni S, Li ZY, Gaggar A, DiPaolo N, Feng Q et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 2005; 79: 5090–5104.
Sova P, Ni S, Ren X-W, Bernt K, Lieber A . Efficacy of tumor-targeted and conditionally replicating oncolytic adenovirus expressing Apo2/TRAIL in treatment of liver metastases in a mouse xenograft model. Mol Ther 2004; 9: 496–509.
Di Paolo N, Tuve S, Ni S, Hellström K, Hellström I, Lieber A . Effect of adenovirus mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on anti-tumor immune responses. Cancer Res 2006; 66: 960–969.
Bernt KM, Ni S, Tieu AT, Lieber A . Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 2005; 65: 4343–4352.
Nicklin SA, Wu E, Nemerow GR, Baker AH . The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384–393.
Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A . Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478–7491.
Shinozaki K, Suominen E, Carrick F, Sauter B, Kahari VM, Lieber A et al. Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Therapy 2005; 13: 52–59.
Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 114–123.
Acknowledgements
We thank Steve Roffler and Daniel Stone for critical discussions and Steve Hawes for help with statistical analyses. We are grateful to Branka Horvat for providing the transgenic mice. This study was supported by NIH Grants CA080192, HLA078836 and HL-00-008 and grants from the Doris Duke and Avon Charitable Foundations.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Cancer Gene Therapy website (http://www.nature.com/cgt.
Rights and permissions
About this article
Cite this article
Ni, S., Gaggar, A., Di Paolo, N. et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther 13, 1072–1081 (2006). https://doi.org/10.1038/sj.cgt.7700981
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700981
Keywords
This article is cited by
-
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Journal for ImmunoTherapy of Cancer (2018)
-
An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced
Virology Journal (2017)
-
Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes
BMC Cancer (2017)
-
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic
Molecular Therapy - Methods & Clinical Development (2016)
-
Transient Removal of CD46 Is Safe and Increases B-cell Depletion by Rituximab in CD46 Transgenic Mice and Macaques
Molecular Therapy (2013)